替罗非班对ACS介入术后无复流的临床疗效及血管内皮微粒、hs-CRP的影响

汪新良; 刘映峰; 吴宏超; 缪绯; 张杰波

doi:10.13201/j.issn.1001-1439.2015.05.009

替罗非班对ACS介入术后无复流的临床疗效及血管内皮微粒、hs-CRP的影响

- 1 中山市人民医院急救中心(广东中山, 528403);
- 2 南方医科大学珠江医院心血管内科

详细信息

作者简介:
刘映峰,E-mail:liuyingfengpci@hotmail.com

中图分类号: R541.4

收稿日期: 2014-09-15

The effect of tirofiban on curative effect,EMPs and hs-CRP in acute coronary syndrome patients with no reflow phenomenon after PCI

- 1 The Emergency Centre of Zhongshan City People's Hospital, Zhongshan, Guangdong, 528403, China;
- 2 Cardiovascular Department, Zhujiang Hospital, Southern Medical University

Received Date: 15 September 2014

摘要

摘要: 目的:探讨替罗非班对急性冠状动脉综合征(ACS)介入术后无复流的临床疗效及血管内皮微粒(EMPs)、高敏C反应蛋白(hs-CRP)的影响。方法:选取经皮冠状动脉介入术(PCI)后无复流ACS患者70例随机分为试验组和对照组,每组35例。对照组给予硝普钠,试验组给予替罗非班。采用冠状动脉数字减影血管造影(DSA)观察TIMI血流分级;心电图仪检测心电图;流式细胞仪检测EMPs;ELISA检测hs-CRP;随访6个月观察主要心脏不良事件(MACE)。结果:试验组MACE发生率为8.6%,对照组MACE发生率为31.4%,两组比较差异显著(P<0.05);试验组TIMI血流分级、心电图均明显优于对照组,两组比较差异显著(P<0.05);试验组外周血EMPs及hs-CRP水平显著低于对照组,两组比较差异显著(P<0.05)。结论:替罗非班治疗ACS介入术后无复流,可降低冠状动脉内皮细胞损伤和炎症反应,改善PCI术后无复流,值得临床推广使用。
- 急性冠状动脉综合征 /
- 无复流 /
- 经皮冠状动脉介入术 /
- 替罗非班
Abstract: Objective:To evaluate the effect of tirofiban on curative effect,endothelial microparticles(EMPs) and high sensitivity C-reactive protein(hs-CRP) in acute coronary syndrome(ACS) patients with no reflow phenomenon after percutaneous coronary intervention(PCI).Method:Seventy patients with ACS who had no-reflow phenomenon during PCI were randomly divided into control group and treatment group,35 cases in each group.Tirofiban was used in treatment group and sodium nitroprusside was used in control group.Used coronary arterial digital subtraction angiography(DSA) to observe TIMI myocardial perfusion grade,electrocardiograph to detect electrocardiogram,flow cytometry instrument to detect blood EMPs,ELISA to detect hs-CRP and followed up for 6 months to observe the major adverse cardiac events(MACE).Result:The rate of MACE was 8.6%in treatment group,31.4%in control group,showed significant differences between the two groups(P<0.05).The TIMI myocardial perfusion grade and electrocardiogram in treatment group were significantly better than those in control group.The difference was statistically significant(P<0.05).The levels of EMPs and hs-CRP in peripheral blood in treatment group were significantly lower than those in control group,the differences were statistically significant(P<0.05).Conclusion:The treatment with tirofiban through coronary artery can reduce coronary endothelial cell injury and inflammation and relieve no-reflow effectively after PCI.
- acute coronary syndrome /
- no reflow phenomenon /
- percutaneous coronary intervention /
- tirofiban

HTML全文

参考文献(13)

[1]	MEGA J L, BRAUNWALD E, WIVIOTT S D, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366:9-19.
[2]	BOLAD I A, KHAN B, GHUMMAN W. Contrast-induced coronary no-flow phenomenon during diagnostic coronary angiography[J]. Tex Heart Inst J, 2011, 38:600-607.
[3]	XU Q, YIN J, SI L. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI[J]. Int J Cardiol, 2013, 162:210-219.
[4]	ANDERSON J L, ADAMS C D, ANTMAN E M, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 123:426-579.
[5]	DING S, PU J, QIAO Z, et al. TIMI myocardial perfusion frame count:A new method to assess myocardial perfusion and its predictive value for short-term prognosis[J]. Catheter Cardiovasc Interv, 2010, 75:722-732.
[6]	BROSH D, ASSALI A R, MAGER A, et al. Effect of no-flow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality[J]. Am J Cardiol, 2007, 99:442-445.
[7]	张海涛,杨跃进,吴以岭,等.通心络预给药2小时对猪急性心肌梗死再灌注后心肌微血管内皮结构完整和无再流的保护作用[J].中华医学杂志, 2009, 89(20):1421-1425.
[8]	卢均坤,王燕琴,贺兆发.内皮细胞损伤对于经皮冠状动脉介入术后血流的意义[J].心血管康复医学杂志, 2010, 19(3):262-264.
[9]	AKTURK I F, YALCIN A A, SARIKAMIS C, et al. Treatment of coronary no-reflow with intracoronary vasodilators added to intravenous tirofiban[J]. J Am Coll Cardiol, 2013, 62:4-8.
[10]	陆永光,文宏,曾书燚,等.替罗非班对冠脉无复流患者内皮微粒和可溶性细胞间黏附分子-1的影响[J].实用医学杂志, 2010(9):1540-1543.
[11]	SAKA K, HIBI K, MAEJIMA N, et al. Effect of microchannel and hs-CRP levels on the incidence of in-stent restenosis in patients with acute coronary syndrome[J]. Eur Heart J, 2013, 34:3963-3969.
[12]	张红雨,王佩显,曹艳君,等.冠状动脉内注射替罗非班对急性心肌梗死患者介入治疗中无复流现象的疗效研究[J].临床心血管病杂志, 2011, 27(1):25-29.
[13]	张玉东,薛涛.替罗非班在老年人急诊经皮冠状动脉介入治疗中预防无复流的临床观察[J].中华老年心脑血管病杂志, 2011, 13(10):880-882.